Disitamab Vedotin or Endocrine Therapy for Patients With Metastatic Breast Cancer With Hormone Receptor-positive and HER2-low-expression
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 288
- 试验地点
- 3
- 主要终点
- Progression free survival (PFS)
研究概览
简要总结
Hormone receptor positive, HER2-low expression metastatic breast cancer is the main type of breast cancer, accounting for about 50% - 60%. However, this type of patients lack ideal therapeutic drugs after the failure of first-line standard endocrine therapy, and the median overall survival time is only 30 months. Therefore, finding more efficient and safe therapeutic drugs for these patients has become a big clinical challenge at present. Disitamab Vedotin (DV), as a new class I Antibody-Drug Conjugates drug, can achieve high efficiency and precise tumor killing effect with low toxicity. According to previous study with same sample size, DV also showed good efficacy in metastatic breast cancer with Hormone receptor positive and HER2- low expression as a posterior line treatment.Therefore, we intend to explore the efficacy and safety of DV in the treatment of HER2-low expressioin /Hormone receptor positive metastatic breast cancer patients with endocrine resistance through a scientifically designed, randomized, phase III clinical study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult female patients (aged 18-70 years, including 18 and 70 years) with metastatic breast cancer confirmed by pathology or imaging are not suitable for surgical resection or radiotherapy for the purpose of cure;
- •Pathological examination confirmed that ER and / or PR were positive, and HER-2 was low expression (ER expression: immunohistochemical staining of tumor cells ≥ 10%; PR expression: immunohistochemical staining of tumor cells ≥ 10%; HER2-low: immunohistochemical staining of 2 + and FISH is not expanded, IHC 1 +);
- •Patients who have received endocrine therapy ;
- •According to the efficacy evaluation criteria for solid tumors (RECIST) version 1.1, there is at least one evaluable target lesion or only osteolytic bone metastasis;
- •Patients with stable brain metastasis or asymptomatic brain metastasis;
- •ECOG physical condition score ≤ 2 points, and the estimated survival time is not less than 3 months;
- •Prior treatment-related toxicity must be relieved to ≤ 1 degree (according to NCI CTCAE 5.0) before enrollment (except for hair loss or other toxicity that is considered as no risk to the safety of patients according to the judgment of the researcher);
- •Adequate bone marrow functional reserve: a. WBC ≥ 3.0 × 10 ^ 9 ／ L, b. Neutrophil count (ANC) ≥ 1.5 × 10 ^ 9 ／ L, c. Platelet count (PLT) ≥ 70 × 10^9／L;
- •Liver, kidney and heart function tests were basically normal within one week before enrollment (based on the normal values of laboratories in each research center): A. total bilirubin (TBIL) ≤ 1.5 × upper limit of normal value (ULN), B. alanine aminotransferase (ALT / AST) ≤ 2.5 × ULN (liver metastasis patients ≤ 5xuln), C. serum creatinine ≤ 1.5 × ULN or creatinine clearance rate (CCR) ≥ 60 ml / min; d. left ventricular ejection fraction (LVEF) ≥ 55%, e. QTcF(Fridericia correction) ≤ 470 ms;
- •Patients understand the research process, voluntarily participate in the research, and sign the informed consent form.
排除标准
- •Patients who had received chemotherapy, radiotherapy, immunotherapy, and endocrine therapy for breast cancer within 2 weeks before enrollment.;
- •Patients who had performed major surgery within 2 weeks before enrollment.
- •Severe heart disease or discomfort within 12 months, including, but not limited to, the following: unstable angina pectoris, myocardial infarction, cerebral hemorrhage and cerebral infarction (except for silent lacunar cerebral infarction without treatment);
- •Have active autoimmune diseases (such as corticosteroids or immunosuppressive drugs) requiring systemic treatment in the past 2 years, excluding those with adrenal insufficiency requiring corticosteroid replacement therapy;
- •Have a clear history of neurological or mental disorders, including epilepsy or dementia;
- •According to the judgment of the researchers, there are some accompanying diseases that seriously endanger the safety of patients or affect patients to complete the study.
- •Those who have been known to have allergic history to Disitamab Vedotin or similar drugs;
- •According to the estimation of the investigator , the patient's compliance with the clinical study is insufficient or the researcher believes that there are other factors that are not suitable for the study.
研究组 & 干预措施
Disitamab Vedotin
Disitamab Vedotin, 2mg/kg, every 2 weeks
干预措施: Disitamab vedotin (Drug)
Endocrine therapy
Doctors choose endocrine therapy independently
干预措施: Endocrine therapy (Other)
结局指标
主要结局
Progression free survival (PFS)
时间窗: 24 months
The interval from the date of randomization to the first imaging confirmed progression of disease or death from any cause.
次要结局
- Psychological condition assessed by GAD-7(12 months)
- Overall survival (OS)(36 months)
- Objective response rate (ORR)(12 months)
- Quality of life assessed by EORTC-C30(12 months)
- Incidence of adverse events(AE)(from the date of enrollment to one year)
- Disease Control Rate (DCR)(12 months)
- Clinical Benefit Rate (CBR)(12 months)
- Pittsburgh Sleep Scale(12 months)
- Biomarkers and treatment sensitivity analysis(12 months)
研究者
Ying Wang
Associate Professor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University